Clinical Evidence

Our clinical programs are leading the field

Explore the scientific evidence supporting GRAIL’s multi-cancer early detection approach, including peer-reviewed publications and presentations at leading medical congresses. Together, these data highlight test performance, clinical utility, and progress toward transforming cancer screening.

Jump to:

Foundational data

Case-control study

Annals of Oncology

Read Full Article

Clinical Performance

Prospective screening study

Nature Medicine

Read Full Article

Clinical Utility

Randomized control study

Nature Medicine

Read Full Article

Performance in Medicare

Real-World Experience

Prospective real-world study

Nature Communications

Read Full Article

Featured evidence

European Society for Medical  Oncology (ESMO) 2025

Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study

See Presentation

JCO Precision Oncology

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes of Analysis

Read Full Article

Cancer Prevention Research

Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches

Read Full Article

American Association of Cancer Research (AACR) 2026

Association Between Emergency Department (ED) Involvement in Cancer Diagnosis and Survival Across Cancer Types in the Medicare Population

See Presentation

Manuscripts

BMJ Open

Assessment of the impact of multi-cancer early detection test screening intervals on late-stage cancer at diagnosis and mortality using a state-transition model

May 8, 2025

View Manuscript

Cancer Research Communications

Modeled Benefit of Individual Cancer Signal Origin Prediction for Multi-Cancer Early Detection

May 5, 2025

View Manuscript

Cancer Prevention Research

Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution Following Multi-Cancer Early Detection Testing in the PATHFINDER Study

April 23, 2025

View Manuscript

Clinical Cancer Research

Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection

April 8, 2025

View Manuscript

Cancer Biomarkers

Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States

March 20, 2025

View Manuscript

Cancer Medicine

Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care Screening

March 17, 2025

View Manuscript

Presentations

EDCC

Baseline Participant Characteristics From PATHFINDER 2, a Prospective Interventional Study of a Multi‑Cancer Early Detection Test in a Population Setting

October 21, 2025

View Presentation

EDCC

Molecular Cancer Signal Localization in Multi-Cancer Early Detection (MCED) Testing Minimizes Radiation and Imaging Burden Compared to Whole-Body Imaging Approaches

October 21, 2025

View Presentation

EDCC

NHS-Galleri Trial: Approaches to Retain a Diverse Participant Cohort Across Multiple Trial Appointments

October 21, 2025

View Presentation

ESMO

Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended Use Population: Initial Results from the Registrational PATHFINDER 2 Study

October 18, 2025

View Presentation

ESMO

Clinical Performance of a Blood-Only, Targeted Methylation Circulating Tumor DNA (ct DNA) Assay for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRD)

October 18, 2025

View Presentation

AACR Cancer Health Disparities

Baseline Participant Characteristics From PATHFINDER 2, a Prospective Interventional Study of a Multi‑Cancer Early Detection Test in a Population Setting

September 20, 2025

View Presentation